Can Exercise Be a Part of Cancer Treatment? | Dana-Farber Cancer Institute
Researchers at Dana-Farber are exploring the possibility that exercise could be specifically prescribed as medicine for cancer patients.
Researchers at Dana-Farber are exploring the possibility that exercise could be specifically prescribed as medicine for cancer patients.
Registration for the OncoAlert ASCO 5k to be held on June 1st, 2024 at 7am local time and will start at the Hyatt Regency McCormick…
The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.
MRI-guided treatment could be used to optimize the duration of neoadjuvant chemotherapy in hormone receptor-negative/HER2-positive breast cancer.
A unique approach combining genomic and sensitivity testing with machine learning was feasible for guiding treatment selection in pediatric cancers.
Open access journal of the Ferrata-Storti Foundation, a non-profit organization Open access journal of the Ferrata-Storti Foundation, a non-profit organization Montgomery Cancer Center, Prattville Campus,…
The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.
Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.
Idalid Franco, MD, MPH, discusses the integration of immunotherapy, molecular biomarkers, and risk factors for recurrence into the endometrial cancer paradigm.
The FDA granted accelerated approval to tovorafenib for pediatric patients relapsed/refractory low-grade glioma with a BRAF fusion/rearrangement or a BRAF V600 mutation.
The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR)–positive GEP-NETs.